RxDoctor Payments Data

Robert Sterling, MD

Orthopaedic Surgery · Washington, DCNPI 1396782603

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (48.2%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 15 manufacturers reported payments, led by Zimmer Biomet at 43.2% of the total. Reporting peaked in 2022 at $27,233 and has fallen 92.7% since, to $1,991 in 2025.

$37,564in general payments, 2019–2025

Across 109 payments — averaging $344.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Zimmer Biomet$16K
  • Smith+Nephew$14K
  • Regeneron$3K
  • Encore Medical, LP$3K
  • Microport Orthopedics Inc$537
  • Stryker$351
  • plus $1K from 9 others

What the payments were for

  • Consulting fees$18,09848%
  • Speaking & faculty fees$8,62523%
  • Travel & lodging$6,33117%
  • Food & beverage$4,46412%
  • Education$470%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$37,564 in reported general payments places this provider in the 85th percentile of 46 orthopaedic surgery providers in District of Columbia.

See all orthopaedic surgery providers in District of Columbia

Medicare billing

Part B allowed, 2024
$140,118
Medicare patients
257
Services billed
1,117

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Diclofenac Sodium78$1,006
Celecoxib18$686
Etodolac29$455
Naproxen22$291
Meloxicam51$131
Mupirocin15$118

Paid to pharmacies, not to this prescriber.

Other orthopaedic surgery in Washington

See the full list for District of Columbia

Where these figures come from

Is this you, or does something look wrong? →